Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Increase in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 273,000 shares, an increase of 134.9% from the December 31st total of 116,200 shares. Based on an average daily trading volume, of 242,400 shares, the short-interest ratio is presently 1.1 days. Approximately 6.3% of the shares of the stock are short sold.

Vivos Therapeutics Trading Down 7.3 %

VVOS stock opened at $3.93 on Friday. Vivos Therapeutics has a 12 month low of $1.91 and a 12 month high of $7.74. The company’s 50 day simple moving average is $4.48 and its 200-day simple moving average is $3.29.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Alliance Global Partners decreased their price target on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 19th. Ascendiant Capital Markets reissued a “buy” rating and issued a $6.60 target price on shares of Vivos Therapeutics in a report on Wednesday, November 20th.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.